TRAIL has gained much attention for its speci®c induction of apoptosis in cancer cells but not in normal cells. This phenomenon has been explained thus: that cancer cells dominantly express death receptors while normal cells express decoy receptors. However, recent reports have shown that some cancer cell lines are resistant to TRAIL-induced apoptosis despite the absence of decoy receptors and the presence of death receptors. This suggested the existance of an inhibitory factor. We herein showed that NF-kB is a key molecule underlying the TRAIL-resistant mechanism in renal cell carcinoma (RCC) cell lines. We observed that NF-kB is constitutively activated in resistant cell lines. Forced expression of antisense cDNA of IkBa, a speci®c inhibitor of NF-kB, in TRAIL-sensitive cell lines with a low NF-kB activity result in constitutive activation of NF-kB and resistance to TRAIL-induced apoptosis. Adenoviral expression of a stable form of IkBa in the TRAIL-resistant cell lines induced apoptosis. These data suggest that RCC can be classi®ed into two subsets: TRAIL-sensitive RCC with a low NF-kB activity and TRAIL-resistant RCC with constitutively activated NFkB. In the former group TRAIL can be a treatment option, while in the latter group a molecular approach targeting NF-kB appears to be a promising therapy. Oncogene (2001) 20, 3888 ± 3896.
Introduction
Apoptosis is a type of cell death in which specialized signal transduction plays a role. Recent advances in clarifying this`programmed cell death' have prompted clinicians to design new therapeutic approaches aimed at stimulating the apoptotic responses in cancer cells. The tumor necrosis factor (TNF) family of cytokines and their receptors has been the center of much attention, since the receptors of this family contain`d eath domains' which activate the caspase pathway leading the cells to apoptosis (Ashkenazi and Dixit, 1998) . At present, three major ligand/receptor systems, FasL (Fas-ligand)/Fas (CD95L/CD95), TNF-a/TNFR1 and TRAIL/TRAIL-receptors have been identi®ed. Among these, TRAIL (also known as Apo2L) has gained particular attention because this ligand appears to induce apoptosis in a wide range of cancer cells but not in normal cells (Wiley et al., 1995; Pitti et al., 1996) . This phenomenon can be explained by the speci®c expression of antagonistic receptors in normal cells (Sheridan et al., 1997; Pan et al., 1997) . These receptors are decoy receptors (DcR1 and DcR2) which lack cytoplasmic domains. Normal cells are, therefore, protected from TRAIL-induced apoptosis, while cancer cells which express TRAIL receptors undergo apoptosis. However, there have been con¯icting reports which show that decoy receptors are not limited to expression in normal cells (Frank et al., 1999; Keane et al., 1999) . Furthermore, TRAIL-resistant cancer cell lines have been described despite the absence of decoy receptors and the presence of death receptors (Rieger et al., 1998; Zhang et al., 1999) . The mechanism underlying TRAIL resistance therefore needs to be clari®ed.
After binding TRAIL to its receptors, adaptor proteins such as FADD, TRADD, TRAF1, 2 and 3 bind to receptors and trigger biphasic signal cascades: one is the apoptotic pathway which is initiated by caspase-8; the other is a putative antiapoptotic pathway through the activation of NF (nuclear factor)-kB (Chaudhary et al., 1997) . The aggregation of caspase-8 with adaptor proteins leads to autoprocessed cleavage. Activated caspase-8 is then released into the cytoplasm and initiates a proteolytic cascade involving the other caspases, such as caspase-3, which thus eventually leads to apoptosis (Thornberry and Lazebnik 1998) .
NF-kB is a DNA binding protein that augments the transcription of various genes involved in cell proliferation, such as cytokines and cytokine receptors, and it thus plays a role in cell development, survival and oncogenesis (Baeuerle and Baltimore, 1996) . In quiescent cells, cytosolic NF-kB is bound to inhibitory IkB proteins. Upon signal activation, IkB becomes phosphorylated, ubiquitinated, and subsequentially degraded by proteasomes. This lets activated NF-kB translocate into nucleus and bind to DNA (Verma et al., 1995) . Death-inducing ligands including TNF-a, FasL and TRAIL activate NF-kB (Beg and Baltimore 1996; Ashkenazi and Dixit, 1998) . Recent studies have shown the inhibition of NF-kB activation increases apoptosis sensitivity in lymphoid cells (Jeremias et al., 1998) . NF-kB activation may therefore be a mechanism which underlies the resistance to TRAIL.
Renal cell carcinoma (RCC) can be cured by surgery when detected at an early stage. However, in disseminated cases, chemotherapy and irradiation have been tried without eect. Cytokine therapy, such as Interferon-a and IL (interleukin)-2 has been thought to be a promising treatment, however, the eectiveness is only about 10 ± 20% (Mulders et al., 1997) . A novel therapy for these patients thus needs to be established. A previous study showed that some RCC cell lines are sensitive to TRAIL (Ashkenazi et al., 1999) . Recent in vivo studies have demonstrated the selective cytotoxic activity of TRAIL in SCID mice using a TRAIL-sensitive human mammary adenocarcinoma cell line (Walczak et al., 1999) . As a result of this preferential eect on cancer cells, we investigated eectiveness of TRAIL on RCC cells in light of its potential clinical application.
In the present study, we ®rst examined the correlation of sensitivity to TRAIL and state of its receptors. We next examined the expression of adaptor proteins of TRAIL receptors and caspase-8. However, the expression of these molecules did not correlate with the sensitivity of TRAIL. Finally we showed that the constitutive activation of NF-kB protected from TRAIL-induced apoptosis and that suppression of constitutively active NF-kB by adenoviral expression of a stable form of IkBa had induced apoptosis of TRAIL-resistant cells.
Results

TRAIL induces apoptosis in RCC cell lines
The antiproliferative eect of TRAIL was determined by Alamar Blue assay at 24 h after the treatment. Three cell lines Caki-1, ACHN and A498 were sensitive to TRAIL while the other cell lines, KU-2, KU19-20 and 769P were resistant (Figure 1a ). To assess whether or not apoptosis was induced, the level of fragmented DNA was measured by a fragmented DNA ELISA. After 4 h of TRAIL treatment, the absorbance in all three sensitive cell lines signi®cantly increased. In the resistant cell lines DNA fragmentation was not enhanced (Figure 1b ).
The expression of TRAIL receptors and adaptor proteins does not correlate with the sensitivity to TRAIL The expression of DR4, DR5 (TRAIL receptors), DcR1 and DcR2 (its decoy receptors) was analysed by RT (reverse transcription) ± PCR (Figure 2 ). DR4 was expressed in all the cell lines except KU-2. DR5 was expressed in KU19-20, ACHN, 769P and A498 but not inKU-2 and Caki-1. A prominent DcR1 expression was observed in KU-2, while only a slight expression was seen in A498. The DcR2 expression was observed in KU19-20, ACHN, 769P and A498 but not in KU-2 and Caki-1. The resistance of KU-2 to TRAIL can be explained by no expression of DR4 and DR5 in this cell line. The Caki-1 cell line seems most likely one to undergo apoptosis because this cell line did not express any decoy receptors. However, there was no apparent dierence between sensitive cell lines (ACHN and A498) and the resistant cell lines (KU19-20 and 769P) regarding receptors and decoy receptors. Although KU19-20 and 769P have DR4 and DR5, these cells are insensitive to TRAIL. This insensitivity may be due to a lack of adaptor proteins which conjugate the cytoplasmic domain of receptors and modulate the apoptotic signal cascade. The resistant KU19-20 and 769P expressed FADD, TRADD, and TRAF1, 2, 3. This expression pro®le was not dierent from the sensitive cell line A498. As a result, there was no apparent correlation between sensitivity to TRAIL and the status of the adaptor proteins. The expression of caspase-8 was observed in all the cell lines ( Figure 2 ).
TRAIL-induced apoptosis correlates with the activation of caspase-8
In the¯ow of the apoptotic signal cascade, caspase-8 is the proximal caspase which conjugates the adaptor proteins. Although the resistant KU19-20 and 769P expressed caspase-8 detected by RT ± PCR, caspase-8 was not activated by TRAIL (Figure 3a ). Caspase-3 is consequently activated in the sensitive cell lines (Figure 3b ). Caspase-8 activation is representative of TRAIL-induced apoptosis, therefore, in later studies caspase-8 activation was examined in order to better evaluate apoptosis.
The TRAIL resistant cell lines had constitutively activated NF-kB
Regarding the putative antiapoptotic role of NF-kB, NF-kB may be activated by TRAIL only in resistant cell lines. Therefore, NF-kB activity was evaluated by EMSA (electrophoresis mobility shift assay) after stimulation by TRAIL. Contrary to the speculation, TRAIL induced NF-kB activation in all the cell lines except KU2, which lacks TRAIL receptors ( Figure 4a ). In contrast, basal NF-kB activity before treatment of TRAIL varied cell by cell. Therefore, EMSA was done on the same gel to compare the basal NF-kB activity. Notably, the TRAIL-resistant KU19-20 and 769P had a relatively high basal activity of NF-kB while the sensitive cell lines had a relatively low basal activity ( Figure 4b ). Supershift assay was done using NF-kB p50 antibody to con®rm that the bands are the speci®c binding of NF-kB with the consensus oligonucleotides ( Figure 4c ). In summary, a high NF-kB activity inversely correlated with TRAIL sensitivity. The Constitutive activation of NF-kB alters the TRAILsensitive cell lines resistant to TRAIL-induced apoptosis
To prove this hypothesis, antisense cDNA of IkBa was introduced into TRAIL-sensitive cell lines to establish the cells in which NF-kB is constitutively activated and then the sensitivity of TRAIL was assessed. In Caki-1 and ACHN cell lines, cDNA of IkBa in an antisense orientation was successfully introduced using the retrovirus vector. Immunoblots were done to con®rm the expression of IkBa. EMSA showed the constitutive activation of NF-kB in the stably transfected cells with antisense cDNA of IkBa (Figure 5a ). The stably transfected cell lines Caki-1 (AS) and ACHN(AS) became resistant to TRAIL when evaluated by caspase-8 activation at 3 h (Figure 5b ).
Apoptosis was induced by the infection of AxIkBaDN in the TRAIL resistant cell lines
The constitutive activation of NF-kB may be closely related with the aberrant proliferation of the TRAIL resistant cell lines and a molecular approach targeting NF-kB was employed. The transfection of wild type IkBa could not fully block the NF-kB activity because the expressed IkBa can be promptly degraded by the ubiquitin-proteasome pathway (Verma et al., 1995) . Therefore, a truncated form of IkBa (IkBaDN), which is protected from degradation, was introduced to the adenovirus. As a result, the recombinant adenovirus vector AxIkBaDN was constructed. The eciency of adenovirus infection was evaluated using AxLacZ, which showed that almost all the cells were stained by X-gal at MOI (multiplicity of infection) of 10 for 24 h (data not shown). Therefore, infection of AxIkBaDN at MOI of 10 was applied to the following experiments. At 48 h after the infection of AxIkBaDN, the cell viability decreased notably in the TRAILresistant cell lines KU19-20 and 769P (Figure 6a ). In the sensitive cell lines, induction of apoptosis was observed by fragmented DNA ELISA (Figure 6b ). Immunoblots were done to con®rm the protein expression of IkBaDN in KU19-20 and 769P cells as well as in Caki-1 (Figure 6c ). EMSA was done to con®rm that the infection of AxIkBaDN fully suppressed the activity of NF-kB in KU19-20 and 769P as well as in Caki-1 cells (Figure 6d ). AxIkBaDN can be a novel therapy for TRAIL-resistant RCC with high NFkB activity.
Discussion
Recent studies have shown that TRAIL receptors are not speci®cally expressed in cancer cells, while decoy receptors are not speci®cally expressed in normal cells (Frank et al., 1999; Keane et al., 1999) . Furthermore, several reports have demonstrated that TRAIL-induced apoptosis does not entirely depend on the expression of TRAIL receptors versus decoy receptors (Rieger et al., 1998; Zhang et al., 1999) . Zhang et al. (1999) reported that some melanoma cell lines are resistant to TRAILinduced apoptosis, despite the absence of decoy receptors and moderate levels of TRAIL receptors. These phenomena may be explained by the presence of inhibitors within the cells. The expression of a caspase inhibitor, FLIP may be a candidate for the inhibitor of TRAIL-induced apoptosis. Kim et al. (2000) reported that FLIP could be a predictor of TRAIL sensitivity, but Zhang et al. (1999) showed no correlation. The mechanism underlying the resistance in the TRAILinduced apoptosis remains to be elucidated. In our studies, in accordance with the above reports, the expressions of TRAIL receptors versus decoy receptors alone were not sucient to predict TRAIL-induced apoptosis. The adaptor proteins of TRAIL receptors, which are implicated in the mediation of apoptosis, were also unable to predict the sensitivity to TRAIL. The function of more distal molecules should thus be investigated.
In the signal cascades inducing the cells to undergo apoptosis by TRAIL, caspases are key enzymes, caspase-8 especially, as the key protease which initiates the signal cascade. Indeed in the present study the activation of caspase-8 correlated with TRAIL-induced was not activated by TRAIL. The other signal cascade triggered by TRAIL is a putative antiapoptotic cascade which activates NF-kB. In all the cell lines, except KU2 which was devoid of any TRAIL receptors, NFkB was activated by TRAIL. In contrast, TRAILresistant cell lines had high NF-kB activity, while sensitive cell lines had low activity. We thus postulated that the constitutive activation of NF-kB can prevent TRAIL-induced apoptosis, and to prove this hypothesis, cDNA of IkBa, a speci®c inhibitor of NF-kB, was introduced to TRAIL-sensitive cell lines with a low NF-kB activity in an antisense orientation to obtain cells in which NF-kB is constitutively activated. Interestingly, sensitive cell lines thus became resistant to TRAIL-induced apoptosis. Activating NF-kB itself did not correlate with TRAIL resistance. In contrast, the constitutive activation of NF-kB can protect cells from TRAIL-induced apoptosis. Accordingly, KothnyWilkes et al. (1998) demonstrated that the pretreatment of IL-1, an activator of NF-kB, protected transformed keratinocytes from TRAIL-induced apoptosis. Thus, one could conclude that NF-kB plays a protective role in the apoptotic signal cascade. The mechanism by which the constitutive activation of NF-kB antagonizes TRAIL-induced apoptosis remains to be elucidated. NF-kB dependent proteins might interfere with caspase-8 activation. Antiapoptotic genes c-IAP1 and c-IAP2 regulated by NF-kB might be candidates (Wang et al., 1998) . NF-kB has been implicated to be associated with an aberrant proliferation and an increased survival in many tumor cells (Beg and Baltimore, 1996) . Jeremias et al. (1998) showed that the inhibition of NF-kB activation augments death-inducing ligands and druginduced apoptosis, and signi®cantly decreases apoptosis resistance. In our study using RCC cell lines, blocking NF-kB activation by overexpressing AxIkBaDN induced apoptosis by itself instead of augmenting the eect of TRAIL. This suggests that NF-kB plays an important role in maintaining the cell to survive and may be related to the oncogenesis of NF-kB in RCC cells, especially in the TRAIL resistant KU19-20 and 769P cells. Beauparlant et al. (1994) showed that the expression of IkBa antisense resulted in the constitutive activation of NF-kB and oncogenic transformation of NIH3T3 cells. The oncogenic role of NF-kB was observed in leukemia and lymphoma (Gilmore et al., 1996) , breast cancer (Sovak et al., 1997) and pancreas cancer (Wang et al., 1999) . However, the role of NF-kB in RCC oncogenesis has not yet been described. In clinical observations RCC is occasionally associated with paraneoplastic syndrome such as leukocytosis and/or in¯ammatory reactions (Ritchie and Chisholm, 1983) . The prognosis of these patients is poor and cytokine dependent autocrine and/ or paracrine growth has been suggested in the development of RCC (Blay et al., 1997) . In cancer cells in which aberrant growth is regulated by cytokines, NF-kB may be constitutively activated because NF-kB is an important transcription factor which induces a variety of cytokine expressions. In accordance with these speculations KU19-20 cells were established in our institution from a patient with paraneoplastic syndrome (marked leukocytosis and in¯ammatory reactions). KU19-20 cells produce cytokines including IL-6, IL-8 and G-CSF (granulocytecolony stimulating factor) (Tachibana et al., 2000) . The inhibition of NF-kB activity could be a novel approach to break the vicious cycle of cell proliferation driven by cytokine production. Our results showed that the constitutive activation of NF-kB in RCC cell lines and in these cells TRAIL had no eect, however, the adenovirus-mediated IkBa overexpression inhibited cell growth by inducing the cells to undergo apoptosis. This novel gene therapy can be applicable to treat RCC, especially in the aggressive phenotype with paraneoplastic syndrome mentioned above.
In summary, we herein demonstrated direct evidence of the regulating role of NF-kB in TRAIL-induced apoptosis. Our data suggest that RCC could be classi®ed into two subsets: TRAIL-sensitive RCC with a low NF-kB activity and TRAIL-resistant RCC with constitutively activated NF-kB. In the former group, TRAIL can be a treatment option, while in the latter group, gene therapy targeting NF-kB appears to be a promising treatment modality.
Materials and methods
Cell lines and culture
All six RCC cell lines were cultured in RPMI 1640 medium (Gibco ± BRL, Grand Island, NY, USA) with 10% fetal bovine serum, streptomycin (100 mg/ml; Gibco ± BRL) and penicilin (100 mg/ml; Gibco ± BRL). KU-2 and KU19-20 are cell lines established in our institute. Caki-1, ACHN, 769P and A498 were purchased from the American Tissue Culture Collection (Rockville, MD, USA).
Cell viability assay
For testing sentivity to TRAIL (TRAIL, soluble recombinant kit, Alexis Biochemicals, San Diego, CA, USA), 100 ml of cell suspension (5610 4 cells/ml) was seeded in¯at-bottom 96-well plates. After 24 h the cells were treated with TRAIL (0.1 mg/ ml). The cell viability was determined by Alamar Blue Assay (Iwaki Glass Co., Chiba, Japan). At period of 24 h treatment 10 ml of Alamar Blue was added and thereafter was incubated for another 3 h. The intensity of the color development was assayed with an ELISA plate reader at a 570/600-nm wavelength. Each experiment was performed in triplicate.
Fragmented DNA detection by ELISA The cell suspension was made at a concentration of 5610 4 cells/ml and seeded 500 ml to each well of¯at-bottom 12-well plates. At 4, 8 h after treatment with TRAIL (0.1 mg/ml), the cells were resuspended in 500 ml of the lysis buer (Cell Death Detection ELISA kit, Boehringer Mannheim, Indianapolis, IN, USA) and incubated for 30 min on ice. After centrifugation supernatants containing low molecular weight fragmented DNA were taken. The presence of fragmented DNA was assayed by two-site ELISA employing anti-histon RT ± PCR detection of TRAIL receptors, decoy receptors and adaptor proteins
Total RNA was isolated from precon¯uent cells by guanidinium acid/phenol/chlorform extraction. Two mg of RNA was reverse transcribed using oligo (dT) primer (Sigma, St Louis, MO, USA) and avian myeloblastosis virus (AMV) reverse transcriptase (Promega, Madison, WI, USA). PCR ampli®cation was carried out using 1 ml of cDNA in the 50 ml PCR mix containing 16reaction buer (TaKaRa, Tokyo, Japan), 200 mM dNTP, 1 pmol each sets of primers and 2.5 units of Taq DNA polymerase (all TaKaRa). The house keeping gene, GAPDH was used as a control. The PCR conditions were basically 35 cycles of 1 min at 958C, 1 min at 558C, and 1 min at 728C. For DR4, DcR1 and DcR2, the annealing temperatures were 60, 59 and 528C respectively. The sequences for the relevant primers were as follows: DR4: Electrophoretic mobility shift assay (EMSA) and supershift assay Cells seeded on 6 cm culture dishes at a concentration of 5610 5 cells/ml were treated with TRAIL (0.5 mg/ml) for 30, 60, 120, 180 min. The cells were then washed with PBS three times and resuspended by 100 ml of lysis buer (20 mM HEPES (pH 7.9), 0.2% NP-40, 10% glycerol, 400 mM NaCl, 0.1 mM EDTA, 1 mM dithiothreitol (DTT), 1 mM sodium vanadate, 0.5 mM PMSF (all Sigma) and protease inhibitor mix (Complete protease inhibitor cocktail set, Boehringer ± Mannheim)) and then were incubated on ice for 15 min. Lysates were centrifuged at 12 000 g for 5 min and the supernatants were stored at 7808C. Fifteen micrograms of supernatants were incubated with poly dIdC (3 mg; Amersham Pharmacia Biotech, Buckinghamshire, UK) in a binding buer (10 mM Tris (pH 7.5), 50 mM NaCl, 0.5 mM EDTA, 1 mM MgCl 2 , 0.5 mM DTT and four vol % glycerol) for 20 min at room temperature. Next the samples were mixed with double-stranded oligonucleotides for the consensus binding sites of NF-kB (5'-AGTTGAGGG-GACTTTCCCAGGC-3') labeled with g-32 P-dATP by T4 polynucleotide kinase (New England Biolabs Inc. Beverly, MA, USA). For supershift assay 2 mg of NF-kB p50 rabbit polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) was added to binding reactions. Protein-oligo mixtures were separated on a non-denaturing 4% polyacrylamid gel in 0.56TBE. The gels were then dried and exposed to an Imaging plate overnight and then were analysed using FLA2000 (Fuji Film Company, Tokyo, Japan). For speci®c competition, proteins were preincubated with doublestranded unlabeled NF-kB binding oligonucleotide or mutant oligonucleotide (5'-AGTTGAGGCGACTTTCCCAGGC-3') at a 100-fold molar excess.
Assay for caspase-3 and 8
The cells seeded on 6 cm culture dishes at a concentration of 5610 5 cells/ml were treated with TRAIL (0.5 mg/ml) for 30, 60, 120, 180 min. The activation of caspase-3 and -8 was assayed by an ApoAlert colorimetric assay kit according to user's manual (Clontech Lab. Inc., Palo Alto, CA, USA). The cells were lysed and 100 mm of protein were used to evaluate the activities. DEVD (Asp-Glu-Val-Asp)-pNA (p-nitroanilide) and IETD (Ile-Glu-Thr-Asp)-pNA were used, respectively, as substrates for caspase-3 and caspase-8. Colorimetric detection was performed in a spectrophotometer at 405 nm.
Introducing antisense IkBacDNA in an antisense orientation into renal cancer cells
Human IkBacDNA was subcloned into the EcoRI site of the retroviral expression vector pMx-puro in sense or antisense orientation. Retroviruses were produced in the packaging cell line Pheonix-Ampho. The infected RCC cell lines were selected with puromycin (2 mg/ml).
Construction of adenovirus vector (AxIkBaDN)
A recombinant adenovirus vector which expresses a stable form of IkBa (AxIkBaDN) was constructed as previously reported (Sumitomo et al., 1999) . This stable form deletes the NH 2 -terminal 54 amino acids of the wild type. Virus stocks were puri®ed with two round CsCl step gradient centrifugation. As a control vector, AxLacZ containing the CAG promotor, lacZ gene, and poly(A) + signal sequences was used. To optimize infection condition, cells were infected with AxLacZ (MOI of 1, 5, 10, 50) for 24, 48 and 72 h and then stained with X-gal for 12 h at 378C.
Immunoblotting
Cells were washed twice with PBS, scraped o the plate, and then lysed with the lysis buer described above at EMSA in Materials and methods. The extracts were centrifuged at 12 000 g for 10 min at 48C. The extracted protein (20 mg) with sample buer containing 2-mercaptoethanol were separated on SDS ± PAGE (sodium dodecyl sulfate-polyacrylamide gel). The gels were blotted onto a PVDF membrane using a semidry method. The membrane was incubated with 5% skim milk in PBS overnight. The primary antibody used was rabbit antiIkBa polyclonal antibody (Upstate Biotechnology, Lake Placid, NY, USA). Immunodetection was performed using an enhanced detection system by avidin-biotin complex (Vectastain ABC kit, Vector Lab., Burlingame CA, USA).
